Ratings Aeterna Zentaris Inc.

Equities

AEZS

CA0079755017

Market Closed - Toronto S.E. 03:59:59 2024-03-28 pm EDT 5-day change 1st Jan Change
2.91 CAD +2.83% Intraday chart for Aeterna Zentaris Inc. +5.43% +13.23%

Weaknesses

  • The company has insufficient levels of profitability.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
+13.23% 10.11M - -
+9.30% 45.97B
B
+52.73% 43.93B
A
+7.15% 42.34B
B-
-8.78% 28.27B
C
+18.68% 27.18B
B-
-21.92% 19.44B
B
+14.62% 13.83B
C+
+31.85% 12.4B
C+
+4.47% 11.45B
B+
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes